{"id":"aripiprazole-quetiapine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Sedation"},{"rate":"15-30","effect":"Weight gain"},{"rate":"10-20","effect":"Akathisia"},{"rate":"5-15","effect":"Extrapyramidal symptoms"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"10-25","effect":"Metabolic syndrome"},{"rate":"5-15","effect":"Prolactin elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A partial agonist, while quetiapine is a dopamine D2 and serotonin 5-HT2A receptor antagonist. Together, they modulate dopaminergic and serotonergic neurotransmission to treat psychotic disorders and mood disturbances. This combination approach may provide complementary effects for treatment-resistant conditions.","oneSentence":"This is a combination of two atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:18:06.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Treatment-resistant psychosis"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT01119014","phase":"PHASE4","title":"Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis","status":"COMPLETED","sponsor":"Anne Katrine Pagsberg","startDate":"2010-05","conditions":"Psychosis","enrollment":300},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT06467474","phase":"NA","title":"Psychoeducational Group for Depression","status":"RECRUITING","sponsor":"Ricardo Alberto Moreno, M.D., Ph.D.","startDate":"2024-03-01","conditions":"Major Depressive Disorder (MDD","enrollment":338},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":"Schizophrenia, Metabolic Syndrome X","enrollment":328},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT00149734","phase":"PHASE3","title":"Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2005-01","conditions":"Schizophrenia","enrollment":8},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT02630888","phase":"PHASE2","title":"Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2014-08","conditions":"Bipolar Disorder","enrollment":44},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02526030","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2008-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02305823","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2005-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02534363","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2005-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":136},{"nctId":"NCT00423878","phase":"PHASE4","title":"Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2007-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":215},{"nctId":"NCT02192723","phase":"NA","title":"A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-06","conditions":"Schizophrenia","enrollment":550},{"nctId":"NCT01739127","phase":"","title":"Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2012-11","conditions":"Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X","enrollment":83},{"nctId":"NCT00439634","phase":"PHASE2","title":"Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-02","conditions":"Schizophrenia","enrollment":873},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT01844700","phase":"PHASE4","title":"1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2013-07","conditions":"High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure","enrollment":14},{"nctId":"NCT02650102","phase":"PHASE1, PHASE2","title":"The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2013-01","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT01164059","phase":"PHASE4","title":"Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia","status":"COMPLETED","sponsor":"University of Bremen","startDate":"2010-02","conditions":"Schizophrenia","enrollment":149},{"nctId":"NCT02282085","phase":"PHASE4","title":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","status":"UNKNOWN","sponsor":"Matt Byerly","startDate":"2014-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT01786369","phase":"","title":"Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2013-02","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":106},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT02137616","phase":"NA","title":"Antipsychotic to Treat Psychosis Syndrome","status":"UNKNOWN","sponsor":"Central South University","startDate":"2012-06","conditions":"Psychotic Disorders","enrollment":300},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT02040883","phase":"PHASE4","title":"Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia","status":"UNKNOWN","sponsor":"Qingyun Yin","startDate":"2014-02","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00312598","phase":"","title":"Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-08","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":30},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT00845988","phase":"PHASE4","title":"Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-12","conditions":"Bipolar Disorders, Metabolic Complication","enrollment":28},{"nctId":"NCT00857818","phase":"PHASE3","title":"Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-04","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder","enrollment":64},{"nctId":"NCT00237913","phase":"PHASE3","title":"Schizophrenia Trial of Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":700},{"nctId":"NCT00325689","phase":"PHASE4","title":"Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":323},{"nctId":"NCT01193166","phase":"PHASE4","title":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","status":"WITHDRAWN","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01607762","phase":"PHASE1","title":"A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT01129674","phase":"PHASE2, PHASE3","title":"A Long-Term, Open-Label, Study on Schizophrenia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Schizophrenia","enrollment":1210},{"nctId":"NCT01710163","phase":"PHASE4","title":"Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2012-06","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT00488891","phase":"","title":"The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia","status":"TERMINATED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2007-04","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT01047215","phase":"PHASE4","title":"Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine","status":"UNKNOWN","sponsor":"Taichung Veterans General Hospital","startDate":"2009-08","conditions":"Schizophrenia, Bipolar","enrollment":120},{"nctId":"NCT00304616","phase":"PHASE4","title":"SWitching to Abilify Trial (SWAT)","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2004-10","conditions":"Schizophrenia","enrollment":500},{"nctId":"NCT01016145","phase":"PHASE4","title":"Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2009-04","conditions":"Schizophrenia or Schizoaffective Disorder","enrollment":126},{"nctId":"NCT01000402","phase":"PHASE4","title":"Juvenile Bipolar Disorder Outpatient Program","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2008-02","conditions":"Bipolar Disorder, Attention Deficit Disorder With Hyperactivity","enrollment":150},{"nctId":"NCT00752960","phase":"","title":"DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics","status":"UNKNOWN","sponsor":"Genomas, Inc","startDate":"2007-01","conditions":"Psychoses","enrollment":1000},{"nctId":"NCT00347425","phase":"PHASE3","title":"Switch Study of Existing Atypical Antipsychotics to Bifeprunox","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-12","conditions":"Schizophrenia and Schizoaffective Disorder","enrollment":286},{"nctId":"NCT00528359","phase":"","title":"β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2005-10","conditions":"Schizophrenia","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aripiprazole; Quetiapine","genericName":"Aripiprazole; Quetiapine","companyName":"Taichung Veterans General Hospital","companyId":"taichung-veterans-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder, Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}